Study on Cystic Fibrosis (CF) Market by Infinium Global research is comprehensive presentation of qualitative and quantitative research to identify key trends, growth prospects, drivers, restraints and opportunities in the Global market. The report also deep dives into the sub-segments of Cystic Fibrosis Market by drug class(CFTR modulators, mucolytics, pancreatic enzyme supplements and bronchodilators), by route of administration(inhaled drugs and oral drugs) through main geographies in the Global Market such as North America, Europe, Asia-Pacific and RoW. Browse through over 100 tables and figures to get complete view of the global and regional markets of Cystic Fibrosis over the period of 2017 to 2023.
Cystic fibrosis is a genetic disease that causes continuous lung infections and breathing problem over time. It is a progressive disease. The presence of imperfect gene causes a thick, sticky buildup of mucus in the lungs, intestine liver, pancreas, and other organs. The mucus in the lungs clogs airways and traps bacteria leading to an infection that causes savior lung damage, and respiratory failure. The mucus prevents in the pancreas discharge the digestive enzymes that allow the body to break down food and absorb vital nutrients. This disease is caused by mutation in gene, cystic fibrosis Trans membrane conductance regulator (CFTR) is a membrane protein in vertebrates, a protein required for regulating sweat, mucus and body secretions.
The global Cystic fibrosis market was sized over USD 2.15 billion in 2015. The global Cystic fibrosis market is projected to reach USD 6.67 billion by 2023, growing with a CAGR between 15% and 15.4% from 2017 to 2023. The global market for cystic fibrosis is driven by continued growth of the number of CF patients worldwide. Increasing awareness for cystic fibrosis therapy, technological developments in the R&D and increase in the occurrence of cystic fibrosis are some of the factors likely to drive the global Cystic fibrosis market over the forecast period. However, high cost of treatment and R&D, complicated pathophysiology, and increase in genetic mutation rate are the prime restraining factors to the growth of global Cystic fibrosis market. Nevertheless, rising number of initiatives taken by nonprofit organizations, and presence of flexible policies are will bring more opportunities to the global Cystic fibrosis market over the forecast period.
The report segments the global Cystic fibrosis market by drug class, by route of administration and by region. The global Cystic fibrosis market is segmented on the basis of drug class as CFTR Modulators, Mucolytics, Pancreatic enzyme supplements and Bronchodilators. The CFTR modulator drug class was estimated to account for approximately 44%% of total CF drug revenue share in 2015. On the basis of route of administration it is segmented by inhaled drugs and oral drugs. Oral route accounted for the largest share of nearly 62.7% in 2015.
- Vertex Pharmaceuticals Incorporated
- Gilead, AbbVie Inc
- Novartis AG
- F. Hoffmann-La Roche Ltd
- Merck & Co. Inc.
- AIT (Advanced Inhalation Therapies)
- Teva Pharmaceutical Industries Ltd
Key topics covered:
2. Executive Summary
3. Global Cystic fibrosis Market Overview
4. Global Cystic fibrosis Market: IGR Snapshots
5. Global Cystic fibrosis market by Drug Class (USD Million) 2017 – 2023
6. Global Cystic fibrosis market by Route of Administration (USD Million) 2017 – 2023
7. Global Cystic fibrosis Market Analysis, by Region (USD Million) 2017 – 2023
8. Company Profiles